, a major type of multipotent stromal cells, produces pain relief (antihyperalgesia) that lasts for months. However, studies have shown that the majority of BMSCs are trapped in the lungs immediately after intravenous infusion and their survival time in the host is inconsistent with their lengthy antihyperalgesia. Here we show that long-lasting antihyperalgesia produced by BMSCs required their chemotactic factors such as CCL4 and CCR2, the integrations with the monocytes/macrophages population, and BMSC-induced monocyte CXCL1. The activation of central mu-opioid receptors related to CXCL1-CXCR2 signaling plays an important role in BMSC-produced antihyperalgesia. Our findings suggest that the maintenance of antihypergesia can be achieved by immune regulation without actual engraftment of BMSCs. In the capacity of therapeutic use of BMSCs other than structural repair and replacement, more attention should be directed to their role as immune modulators and subsequent alterations in the immune system.
Results

BMSC induced upregulation of opioid receptors.
We have used a model of chronic orofacial pain with ligation injury of the masseter muscle tendon (TL) to assess BMSC-produced antihyperalgesia 5 . Notably, the pain-attenuating effect of BMSCs was consistently observed in other persistent pain models in both males and females with multiple measures of nociception, including thermal and mechanical pain sensitivity and pain-related conditioned place avoidance 26 . We showed previously that the BMSC-produced antihyperalgesia was attenuated, or pain hypersensitivity rekindled, by naloxone, an opioid receptors antagonist 5 ; and that N-methyl-D-aspartate receptor-mediated trigeminal nociceptive neuronal hyperexcitability was attenuated by BMSCs, an effect also reversed by naloxone 26 . As naloxone may act as an inverse agonist to block opioid receptor constitutive activity, leading to increased pain 27 , we further verified this effect with a neutral opioid receptor antagonist 6-β-naltrexol. Similarly, the BMSC-produced antihyperalgesia was attenuated by 6-β-naltrexol ( Supplementary  Fig. 1a,b) . These results suggest that the antihyperalgesia by BMSCs involves the endogenous opioid system.
Since RNAi of μ-opioid receptors (MOR) in the rostral ventromedial medulla (RVM), a major opioid-containing brainstem site for pain modulation, attenuated BMSC-produced antihyperalgesia 5 , we first examined whether there was a long-term effect of BMSCs on opioid receptor expression in the RVM (Fig. 1a) . At 1w and 8w after infusion of primary BMSC, RT-qPCR showed that MOR, but not δand κ-opioid receptor mRNAs was upregulated ( Fig. 1b ) and western blot confirmed upregulation of MOR proteins in RVM (Fig. 1c ). We have found that BMSCs after multiple passages (≥20 P) lost their antihyperalgesic property 5 and can be used as a control. 20P-BMSCs did not affect MOR expression at 1w but only slightly increased MOR at 8w after infusion ( Fig. 1c ). Compared to 20P-BMSC-treated rats, the MOR protein levels were significantly higher at both 1 and 8 w after treatment with primary BMSCs (Fig. 1c) . Consistently, increased immunostaining against MOR in RVM was observed ( Supplementary Fig. 1c-f ). This phenomenon was not limited to tissue injury pain models. In rats with L5 spinal nerve ligation injury, a model of neuropathic pain, infusion of human BMSCs selectively upregulated MOR mRNA in RVM ( Supplementary Fig. 1h ). These observations indicate that BMSC-produced antihyperalgesia involves long-lasting activation of the endogenous opioid system.
Differential gene expression in primary and 20P-BMSCs. The lasting upregulation of MOR and anti-
hyperalgesia apparently contradicts the kinetics of infused BMSCs in the body. Most intravenously infused MSCs are trapped in the lungs and removed from the system within a few weeks 12, 13 . Utilizing BMSCs isolated from GFP transgenic S-D rats [SD-Tg(GFP)Bal] 28 , we have verified this phenomenon. BMSCs were infused into the rat at 7d after TL. GFP-positive BMSCs were accumulated in the lungs at 6 h and 1d after infusion and very few GFP cells were observed at 7d after infusion ( Supplementary Fig. 2 ). Few GFP cells were seen at the injured site and none was observed in the brainstem. Considering long-lasting effect of BMSCs on MOR and persistent pain, we reasoned that mechanisms other than a direct effect or engraftment of BMSCs underlie their antihyperalgesia.
Previous studies indicate that primary, but not 20P-BMSCs, produced pain relief 5 , suggesting altered BMSC genotype during culturing. Primary and 20P-BMSCs exhibited similar staining intensity for CD90.1 (Fig. 1d ), indicating that BMSC markers maintained their expression in high-passage BMSCs 29 . However, at 8w after BMSC infusion, primary, but not 20P-BMSCs, upregulated MOR gene expression in RVM ( Fig. 1e ), consistent with a lack of antihyperalgesic effect by 20P-BMSCs 5 . Taking advantage of this phenomenon, we compared gene expression of primary and 20P-BMSCs. Utilizing the Inflammatory Cytokines & Receptors PCR Array, we observed differential expression profiles of major cytokines/chemokines and receptors between the primary and 20P-BMSCs ( Fig. 1f -h). Among the 84 genes examined, 50 in primary BMSCs were expressed at a higher level in all 3 samples (≥2-fold) and 26 of them showed greater than 100-fold differences over the 20P-cells. Six genes expressed lower (>2-fold) in primary BMSCs (Fig. 1h ). Genes for ribosomal proteins (Rpl13a and Rplp1), lactate dehydrogenase A and housekeeping protein β-actin (Actb) do not show differential expressions, suggesting normal biochemical activity remained in 20P-BMSCs. Control genes did not show greater than 2-fold differences between primary and 20P-BMSCs ( Fig. 1g , crosses). Higher expression of some genes was further verified with RT-qPCR ( Supplementary Fig. 3 
)
A repertoire of genes for immune mediators and receptors exhibited higher levels of expression in primary BMSCs compared to 20P-BMSCs (Table 1 4, 22, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] ), including genes for chemotaxis-inducing chemokines and their receptors (Cxcl4, Ccl2, Ccl3, Ccl4, Cxcl12 (Sdf-1), Ccr2, Ccr5), anti-inflammatory cytokines and receptors (Tgfb1, Il10, Il10-ra, Il13RA1), proinflammatory cytokines and receptors (Tnf, Il1b, Il18, Tnfrsf1b), and components of the complement pathways (C3, C5). Interestingly, genes for CXCR2 and its ligands (Cxcl1, Cxcl2, Cxcl5, Cxcr2) that are involved in opioid release from immune cells 30 showed higher expression in primary BMSCs. There was simultaneous higher mRNA expression of some receptors and their ligands in primary BMSCs (e.g., Ccl3/4/5-Ccr5, Cxcl1/2-Cxcr2, Ccl5-Ccr1, Il10-Il10ra, Tnf-Tnfrsf1b, Cxcl1/2/5-Cxcr2), suggesting reciprocal interactions with the host immune cells and autocrine signaling of BMSCs. TGFβ1, which was a critical mediator of BMSCs' antihyperalgesia after intrathecal administration 4 , expressed higher in primary BMSCs ( Fig. 1h , Supplementary Fig. 3 ). While higher expression of the anti-inflammatory cytokines and receptors is consistent with antihypergesia, genes of proinflammatory cytokines and complement components may contribute to the effect of BMSCs by promoting chemotactive interactions with immune cells 21 .
BMSC-derived Chemokines as mediators of antihyperalgesia. Differential gene expressions
between antihyperalgesic primary and ineffective 20P-BMSCs suggest a role of BMSC-derived chemokines in BMSC-produced antihyperalgesia. We next chose to evaluate a role of CCL4 since it's mRNA was not detectable in 2 of 3 20P-BMSC samples (Ct over the cut-off in one) and its expression showed the second highest fold change over 20P-BMSCs ( Fig. 1h , Table 1 ). Western blot confirmed very low level of CCL4 in 20P-BMSCs, compared to primary BMSCs ( Fig. 2a ). We then employed a subtraction strategy to assess the role of CCL4 in BMSC-produced antihyperalgesia. Before transplantation, primary BMSCs were transduced with Ccl4 shRNA lentivirus. Figure 2b ,c show the successful transduction of BMSCs and knock-down of Ccl4. Mechanical nociception of the rat was assessed with von Frey filaments 45 . EF 50 (Effective Force50), the derived von Frey filament force (g) that produces a 50% response, was used as a measure of mechanical sensitivity 5 . In TL rats receiving infusion of transduced BMSCs, BMSC-induced increase in EF 50 was significantly reduced, compared to that receiving control shRNA (Fig. 2d) , and the increased MOR expression in RVM was also significantly reduced ( Fig. 2g ).
These results indicate that BMSC-derived CCL4 contributed to their antihyperalgesic effect.
We then examined the role CCL2-CCR2 signaling, the most studied chemoattractant for monocytes, T cells and other immune cells 46 . Both CCL2 and CCR2 genes showed higher expression in primary BMSCs ( Fig. 1h , Supplementary Fig. 3 ). In contrast to primary BMSCs, CCR2 proteins in 20P-BMSCs was almost undetectable ( Fig. 2e ). In the next experiment, primary BMSCs were pretreated with a CCR2 receptor antagonist RS102895 (10 μM for 24 h) before infusion. In TL rats receiving infusion of RS102895-treated cells, BMSC-induced increase in EF 50 was significantly decreased (Fig. 2f) ; and the increased MOR expression in RVM was also significantly reduced ( Fig. 2g ). Since CCR2 has been shown important for MSC homing 38, 39 , we examined whether blocking CXCL12 (SDF-1)-CXCR4 signaling, key to migration of BMSCs to the injured site 4 , led to a reduction of antihyperalgesia. TL rats were pretreated with AMD3100 (plerixafor, 10 mg/kg/day, i.p. for 4 days), an antagonist of CXCL12 receptor CXCR4. AMD3100 did not affect BMSC-produced antihyperalgesia ( Supplementary  Fig. 4 ). These results suggest that pain attenuation after systemic BMSCs involves chemokine interactions with immune cells, but not necessarily involving homing. However, intrathecal BMSCs may escape the lung trapping and CXCR4 signaling appears important for the antihyperalgesia induced by intrathecal BMSCs 4 .
The role of monocytes/macrophages in pain-relieving effect of BMSCs. Our observations
led to a hypothesis that host immune cells relay BMSCs' input through chemotactic interactions to produce long-lasting antihyperalgesia. Monocytes/macrophages have been shown to mediate the BMSC-produced anti-sepsis 22 . Depletion of macrophages attenuated opioid-induced analgesia 47 . To evaluate a role of monocytes/ macrophages, we employed the liposome-encapsulated clodronate (Lipo-Clo) procedure to deplete monocytes/macrophages [48] [49] [50] . Liposome-encapsulated clodronate was injected i.p. 3 times in three days (10 mg/2 ml/
Genes
Fold change Note 
Chemotaxis/migration of immune cells
Proinflammatory cytokines/receptors
Tnf 5019 ± 534 Also stimulate MOR gene expression in neurons 43 .
Il1b 1438 ± 149 Important mediator of inflammatory response.
Il18 1104 ± 61 Inducing interferon-gamma, which leads to activation of macrophage. injection/rat). After the injections, peritoneal cells were collected and labeled with macrophage marker CD11b. The reduced peritoneal macrophage expression was verified by flow cytometry and ED1-immunostaining of spleen sections ( Supplementary Fig. 5a,b ). The Lipo-Clo treatment attenuated BMSC-produced antihyperalgesia.
In rats pretreated with vehicle of Lipo-Clo, the EF 50 s were significantly increased from 3 d post-BMSCs compared to 14d-TL, indicating antihyperalgesia ( Fig. 3a ). However, with Lipo-Clo pretreatment, the EF 50 s were not significantly increased until 14-d after BMSCs when they were still lower than that of veh-treated rats (p < 0.001). When stable antihyperalgesia had been established, post-treatment with Lipo-Clo at 5d after BMSC infusion rekindled hyperalgesia between 8-21 d after BMSC (Fig. 3b ). The MOR mRNAs were also significantly reduced in Lipo-Clo-treated rats (Fig. 3c ).
To further confirm a role of monocytes/macrophage population in BMSCs' antihyperalgesia, we isolated peripheral blood monocytes (MC) from TL rats that received either BMSCs or culture medium treatment ( Fig. 3d ). Flow cytometry showed that 30.9% of gated population was positive for monocyte marker CD11b ( Supplementary Fig. 6a ). This population was further purified by FACS. The isolated monocytes show characteristic CD11b and CD68 immunostaining ( Supplementary Fig. 6b ). Direct intra-RVM injection of monocytes from BMSC-treated animals attenuated hyperalgesia, as compared to monocytes from medium-treated rats (Fig. 3d,e ). The two experiments involving manipulation of monocytes/macrophages provide convergent support for the involvement of monocytes/macrophages in BMSC-induced antihyperalgesia. Interestingly, some markers of M2 macrophages showed increased mRNA expression in monocytes from primary BMSC-treated rats, including Irf4, (d,f) Two-way ANOVA followed by post-hoc comparisons with Bonferroni corrections; (g) One-way ANOVA followed by post-hoc comparisons with Bonferroni corrections. Cropped gel images are shown in 2a, e.g. See Supplementary Figure 9 for full-length blots.
SCIENTIfIC REPORtS | 7: 10107 | DOI:10.1038/s41598-017-10251-y CD206 and CD163 (Fig. 3f, left ). Irf5 and Cxcl10, genes related to M1 macrophage showed decreased expression after BMSCs and Il-6 gene expression was increased in both PRI-BMSC-treated rats (Fig. 3f, right) . These results suggest that BMSCs promote polarization of macrophages toward an anti-inflammatory phenotype.
Monocytes-derived CXCL1 contributes to antihyperalgesia. An intermediate role of MC in
BMSC-produced antihyperalgesia raised a possibility that the pain-relieving effect of BMSCs was mediated by immune mediators from MC. We compared the gene transcription profiles of major rat inflammatory cytokines/ chemokines and their receptors between MC purified from PRI-and 20P-BMSC-treated TL rats (Fig. 4a ). Three genes (Ccl2, Cxcl1 and Ilr1) showed consistent higher levels of expression in three repeated arrays in MC isolated from PRI-BMSC-treated rats (Fig. 4b, Supplementary Fig. 7) . Among the three genes exhibited higher levels, Cxcl1 is related to regulation and release of opioids from immune cells 30, 44 . Thus, we further pursued the role of CXCL1 in BMSCs' antihyperalgesia. The increased Cxcl1 mRNA in PRI-BMSC-treated rats was further verified (Fig. 4c ). We next confirmed that, in MC isolated from rats receiving Ccl4 shRNA-treated BMSCs, Cxcl1 mRNA was dramatically reduced (Fig. 4d ).
CXCL1 can cross the blood-brain barrier 51 . Selective upregulation of CXCL1 in monocytes suggests that CXCL1 may be released and accesses the CNS to relay the effect of BMSCs. To test this possibility, we isolated serum from TL rats that received BMSCs or control medium treatment and observed an increase in CXCL1 in the serum derived from PRI-BMSC treated rats (Fig. 4e ). Further, direct intra-RVM injection of the serum from BMSC-treated rats similarly attenuated hyperalgesia (Fig. 4f ). Pre-incubation of BMSC-serum with anti-CXCL1 antibody significantly attenuated antihyperalgesia of BMSC-serum ( Fig. 4g) . Consistently, MOR mRNAs in the RVM were upregulated in rats treated with serum isolated from PRI-BMSC-treated rats (Fig. 4f ).
CXCR2 signaling in RVM contributes to BMSC-produced antihyperalgesia. CXCL1 belongs to
the CXC chemokine family and signals through its receptor CXCR2. CXCR2 signaling triggers opioid release from immune cells and induces analgesia 30 . Although CXCR2 is also localized in the CNS 52, 53 , there has been no report on potential role of CXCR2 in descending pain modulation. This prompted us to explore whether CXCL1-CXCR2 signaling is involved in central mechanisms of BMSC-produced antihyperalgesia. We first examined whether CXCR2 was localized in the RVM. CXCR2-NeuN double immunostaining showed that CXCR2 was localized in RVM neurons (Fig. 5a ). However, CXCR2 did not show double immunostaining with microglia marker Iba-1 (Fig. 5b, left) and astroglia marker GFAP (Fig. 5b, right) . CXCR2 immunoreactivity was detected in MOR-containing neurons (Fig. 5c ), indicating their colocalization in RVM. In other brain regions examined, CXCR2 immunoreactivity was found in the trigeminal ganglion, subnucleus caudalis of the spinal trigeminal complex, periaqueductal gray, but not in the periventricular nucleus of the hypothalamus (data not shown). CXCR2 immunostaining and Western blot showed that CXCR2 was upregulated in RVM at 1w and 8w after BMSC infusion (Fig. 5d,e ). Further analysis of CXCL1 in cerebrospinal fluid (CSF) showed that BMSC treatment led to increased CXCL1 levels, compared to medium-treated rats (Fig. 5f) , supporting increased CXCL1-CXCR2 signaling in the brain after BMSC infusion.
We then examined whether CXCR2 in the RVM plays a role in BMSC-produced antihyperalgesia. We first tested the effect of two CXCR2 antagonists SB225002 and NVP CXCR2 20 (NVP). SB225002 (100 pmol/500 nl) or NVP (200 pmol/500 nl) was injected into the RVM at 1w and 8w after infusion of BMSCs when EF 50 on the injured side was elevated. Both antagonists produced a significant reduction of EF 50 at the 3 h time point and NVP also reduced EF 50 at 1 h (Fig. 6a,b) , indicating attenuation of antihyperalgesia. Injection of NVP into the site dorsal to the RVM did not affect BMSC-produced antihyperalgesia (n = 4) ( Supplementary Fig. 8 ). We then employed shRNA of Cxcr2 in RVM. Pretreatment with Cxcr2 shRNA Lentivirus significantly attenuated BMSC-produced antihyperalgesia (Fig. 6c ). Transduction of RVM with Cxcr2 shRNA Lentivirus at 8w post-BMSC significantly decreased EF 50 (Fig. 6d ), suggesting rekindling of hyperalgesia. Knockdown of CXCR2 by RNAi of Cxcr2 in RVM was shown by western blot (Fig. 6e ). MOR mRNA levels were decreased after CXCR2 knockdown (Fig. 6f ). Finally, we tested the effect of BMSCs in CXCR2 knockout mice. The chronic constriction injury of the infraorbital nerve (CCI-ION) 54 was produced in mice to induce persistent pain since the mouse masseter tendon was thin and vulnerable to manipulation. We have shown that BMSC attenuated pain hypersensitivity in the CCI-ION model 5 . We did not observe an antihyperalgesic effect of BMSCs in CXCR2 knockout mice while BMSC produced pain relief in the control wild type mice (Fig. 6g) . These results suggest that CXCL1-CXCR2 signaling contributes to BMSC-produced long-lasting antihyperalgesia.
Discussion
We have studied the mechanisms of BMSC-produced antihyperalgesia from a novel immune regulation and endogenous opioid perspective. Our first major finding was that, together with a pain-attenuating effect, BMSCs induced selective upregulation of MOR in the RVM, a key site for endogenous pain modulation. The finding is consistent with our hypothesis that endogenous opioids are involved in BMSCs' antihyperalgesia 5 . This effect of BMSCs may be a global phenomenon since MOR in other pain-related regions also showed upregulation (unpublished observations). The ability of BMSCs to engage the endogenous opioid system has important implications since there has been great interest in searching for ways of activating the endogenous system for pain relief.
Importantly, we show that BMSC-produced long-lasting pain relief involved their interactions with immune cells and subsequent release of immune mediators (Fig. 6h ). Our findings suggest that the maintenance of antihypergesia could be achieved by persistent chemokine signaling in the CNS. This may explain the discrepancy between the BMSCs' lengthy pain-relieving effect and their relatively short survival in the host after systemic transplantation. In the capacity of therapeutic use of MSCs other than structural repair and replacement, more attention needs to be directed on their role as immune modulators.
Our results indicate that chemotactic interactions with host immune cells are key to BMSCs' lasting pain relief. Compared to 20P-BMSCs that are ineffective, a number of chemokines and receptors exhibited higher levels of gene expression in pain-relieving primary BMSCs (also see ref. 29 ). Deletion of Ccl4 and antagonism of CCR2 signaling in BMSCs significantly attenuated their ability to produce antihyperalgesia and MOR upregulation. Both CCL4-CCR5 and CCL2-CCR2 signaling pathways are involved in monocyte chemotaxis 32, 40 . Thus, chemotactic interactions in the circulation may occur immediately after BMSC infusion and subsequent down-stream effect in host immune cells are critical of BMSCs' antihyperalgesia. It should be cautioned that potential roles of additional chemokines cannot be ruled out since chemokines function in a redundant and overlapping fashion 55 and in vivo interactions of BMSCs should involve a cohort of chemoattractants and their receptors.
Thus, BMSC-derived mediators apparently require collaboration of host immune system in producing antihyperaglesia. Our monocytes/macrophages depletion experiments suggest that monocytes/macrophages are targeted by BMSCs to relay their biological effect. After systemic infusion, BMSCs travel to the lungs and show close relationship to macrophages 22 , suggesting a site of interaction between BMSCs and monocytes/macrophages. Monocytes from BMSC-treated animals exhibited selective upregulation of CXCL1 chemokine that is related to opioid release from immune cells 30, 44 . Intriguingly, CXCL1 also showed an increased level in the serum and CSF derived from BMSC-treated TL rats and direct injection of this serum upregulated MOR in RVM and mimicked BMSC's antihyperalgesia. This raises a possibility that BMSC-induced immune mediators may access the brain β-actin was a loading control. CXCR2 proteins were upregulated in RVM at 1w and 8w after injection of BMSC. ***p < 0.001, vs. Med, n = 4/group. Cropped gel images are shown. See Supplementary Figure 9 for fulllength blots. (e) TL rats received primary BMSC or culture medium at 7d post injury and CSF was collected. Compared to medium-treated rats, CXCL1 proteins were increased in CSF at 1w and 8w after injection of BMSC. **p < 0.01; ***p < 0.001, vs. Med, n = 4/group. Statistics: One-way ANOVA followed by post-hoc comparisons with Bonferroni corrections. to facilitate antihyperalgesia. Indeed, CXCL1 readily penetrates the blood brain barrier to reach the brain parenchyma in a matter of minutes 51 .
CXCL1 initiates its biological effect through the receptor CXCR2 that is also localized in the CNS 52, 53 . Antagonism of CXCR2 in RVM counteracted BMSC-produced MOR upregulation and antihyperalgesia, suggesting a critical role of CXCL1-CXCR2 signaling in BMSC-produced pain relief. Relevant to these observations, CXCL1 is neuroprotective during autoimmune demyelination 56 , facilitates opioid analgesia 43 , and potentially antinociceptive against neuropathic pain 57 . We noticed that studies have shown hyperalgesic action of CXCL1-CXCR2 signaling 52, 58, 59 . These phenomena should be understood with a view that the same immune mediators involved in pain sensitization may also be neuroprotective and promote pain relief under certain conditions 60, 61 . Similar dual roles of the same mediator in pain and analgesia have also been observed. Glucocorticoids compounds are anti-inflammatory through activation of their receptors, but activation of glucocorticoid receptors may also be proinflammatory and pronociceptive after injury 62 . Endothelin-B receptors are pro-algesic along with the ability to activate analgesic pathway 63 . While the anti-inflammatory cytokines and receptors Tgfβ, IL10 and IL10ra showed higher expression in primary BMSCs, consistent with BMSCs' pain relieving effect, genes of proinflammatory cytokines Tnf, IL1β and IL18 and complement components C3 and C5 also exhibited higher levels of expression in primary BMSCs. In monocytes isolated from BMSC-treated rats, proinflammatory CCL2 and IL1R showed higher levels of expression. The presence of these inflammatory factors may contribute to the effect of BMSCs by promoting chemotactive interactions of BMSCs with immune cells 21 . Further, TNF may stimulate MOR gene expression in neurons 42 and CXCR2 related ligands CXCL1/2/5 may induce opioid release from peripheral immune cells 43 .
Although our results suggest positive interactions between CXCR2 and MOR, this is rather unexpected. The interaction between chemokine receptors and opioid receptors often leads to heterologous desensitization involving formation of heterodimers 64 , although CXCR2 has been shown not involved in MOR desensitization 65 . The nature of potential interactions between CXCL1-CXCR2 signaling and MOR in the event of BMSC intervention under injurious conditions requires further study. Genotyping was performed by Geno Typing Center of America (Bangor, ME). All behavioral tests were conducted under blind conditions. The rat brain atlas 66 was referred to for identifying and approaching brain structures. All experiments were carried out in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23) and approved by the University of Maryland, Baltimore, Institutional Animal Care and Use Committee, School of Dentistry and School of Medicine.
Methods
Data analysis.
Power analyses were performed based on our previous data to determine the necessary number of animals needed to provide an 80% chance to achieve statistical significance (alpha = 0.05) and minimal number of animals were used in some experiments when statistical significance was achieved. Data are presented as mean (95% confidence interval) for EF 50 s and mean ± S.E.M. for other data. Statistical comparisons were made by ANOVA followed by post-hoc comparisons with Bonferroni corrections. For unbalanced sample size, multiple regressions were performed and Type III sum-of-squares was used to calculate P values (GraphPad Prism). For animals that were subject to repeated testing, ANOVA with repeated measures was used. P < 0.05 was considered significant for all cases.
Additional Methods are available in the online version of the paper.
